Dasatinib promotes the activation of quiescent hematopoietic stem cells in mice.

[1]  Berthold Göttgens,et al.  Functionally Distinct Subsets of Lineage-Biased Multipotent Progenitors Control Blood Production in Normal and Regenerative Conditions. , 2015, Cell stem cell.

[2]  Samuel J. Taylor,et al.  The targeting of human and mouse B lymphocytes by dasatinib. , 2015, Experimental hematology.

[3]  G. Marcucci,et al.  Emerging diagnostic and therapeutic approaches in core binding factor acute myeloid leukaemia , 2015, Current opinion in hematology.

[4]  Allon M. Klein,et al.  Clonal dynamics of native haematopoiesis , 2014, Nature.

[5]  Samuel J. Taylor,et al.  Dasatinib Targets B-Lineage Cells but Does Not Provide an Effective Therapy for Myeloproliferative Disease in c-Cbl RING Finger Mutant Mice , 2014, PloS one.

[6]  E. Pietras,et al.  Re-entry into quiescence protects hematopoietic stem cells from the killing effect of chronic exposure to type I interferons , 2014, The Journal of experimental medicine.

[7]  J. Shin,et al.  High c-Kit expression identifies hematopoietic stem cells with impaired self-renewal and megakaryocytic bias , 2014, The Journal of experimental medicine.

[8]  M. Baccarani,et al.  Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). , 2014, Blood.

[9]  R. Advani,et al.  Bruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomas , 2013, British journal of haematology.

[10]  Cedric E. Dos Santos,et al.  The Src and c-Kit kinase inhibitor dasatinib enhances p53-mediated targeting of human acute myeloid leukemia stem cells by chemotherapeutic agents. , 2013, Blood.

[11]  M. Moore,et al.  KIT Receptor Gain‐of‐Function in Hematopoiesis Enhances Stem Cell Self‐Renewal and Promotes Progenitor Cell Expansion , 2013, Stem cells.

[12]  N. Varin‐Blank,et al.  Targeting early B-cell receptor signaling induces apoptosis in leukemic mantle cell lymphoma , 2013, Experimental Hematology & Oncology.

[13]  K. Stamatopoulos,et al.  Targeting the LYN/HS1 signaling axis in chronic lymphocytic leukemia. , 2012, Blood.

[14]  Samuel J. Taylor,et al.  Flt3 inhibitor AC220 is a potent therapy in a mouse model of myeloproliferative disease driven by enhanced wild-type Flt3 signaling. , 2012, Blood.

[15]  J. Cortes,et al.  Dasatinib for the treatment of Philadelphia chromosome-positive leukemias , 2012, Expert opinion on pharmacotherapy.

[16]  I. Flinn,et al.  Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up , 2012, Leukemia.

[17]  M. Breccia,et al.  The current role of high-dose imatinib in chronic myeloid leukemia patients, newly diagnosed or resistant to standard dose , 2011, Expert opinion on pharmacotherapy.

[18]  J. Montero,et al.  Inhibition of Src Family Kinases and Receptor Tyrosine Kinases by Dasatinib: Possible Combinations in Solid Tumors , 2011, Clinical Cancer Research.

[19]  A. LaCasce,et al.  Phase II Study of Dasatinib in Relapsed or Refractory Chronic Lymphocytic Leukemia , 2011, Clinical Cancer Research.

[20]  R. Flavell,et al.  Myeloid leukemia development in c-Cbl RING finger mutant mice is dependent on FLT3 signaling. , 2010, Cancer cell.

[21]  S. Corey,et al.  Dasatinib Inhibits the Growth of Molecularly Heterogeneous Myeloid Leukemias , 2010, Clinical Cancer Research.

[22]  F. Lee,et al.  Src inhibitor dasatinib inhibits growth of breast cancer cells by modulating EGFR signaling. , 2009, Cancer letters.

[23]  K. Bhalla,et al.  Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KIT D816V. , 2009, Leukemia research.

[24]  Andreas Trumpp,et al.  IFNα activates dormant haematopoietic stem cells in vivo , 2009, Nature.

[25]  G. Superti-Furga,et al.  Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib , 2008, Leukemia & lymphoma.

[26]  T. Suda,et al.  Thrombopoietin/MPL signaling regulates hematopoietic stem cell quiescence and interaction with the osteoblastic niche. , 2007, Cell stem cell.

[27]  Y. Sharma,et al.  Heterozygous kit mutants with little or no apparent anemia exhibit large defects in overall hematopoietic stem cell function. , 2007, Experimental hematology.

[28]  Moshe Talpaz,et al.  Dasatinib (BMS-354825) Tyrosine Kinase Inhibitor Suppresses Invasion and Induces Cell Cycle Arrest and Apoptosis of Head and Neck Squamous Cell Carcinoma and Non–Small Cell Lung Cancer Cells , 2005, Clinical Cancer Research.

[29]  S. Nishikawa,et al.  Expression and function of c-kit in hemopoietic progenitor cells , 1991, The Journal of experimental medicine.